Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of our neuroimaging researchers will lead this study, which has received a grant from the University of Oxford's COVID-19 Research Response Fund.

MRI scanner from the control room

COVID-19 adversely affects the brain. Around 36 per cent of hospitalised patients show symptoms ranging from loss of sense of smell, to strokes, and seizures. Concerns are growing that COVID-19 may cause long-term harmful neurological effects including cognitive impairment, mental health disorders, and chronic breathing difficulties. This may arise from the direct viral invasion of the brain, or autoimmune responses to the infection, or indirect effects of severe systemic illness.

Using magnetic resonance imaging (MRI), a team led by Associate Professor Kyle Pattinson will quantify brain abnormalities associated with COVID-19 infection. Their aim is to collect proof-of-concept data that will leverage funding for further multi-centre research collaborations. The eventual outcome will be brain markers to direct individualised treatments improving both short- and long-term outcomes from COVID-19.

The team will undertake two observational studies: an acute study in hospitalised patients and a follow-up study, using high-resolution brain-stem MRI, performed 3-6 months later, after patients have been discharged from hospital. In this way, the researchers will be able to characterise the brain structural, functional, and cerebrovascular effects of COVID-19 infection, establish quantitative relationships between clinical/bedside measures of COVID-19 and neuroimaging measures, and provide preliminary data sets for future discovery of novel biomarkers.

Similar stories

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'

Discovery of gene involved in chronic pain creates new treatment target

Our researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord. This is helping them to understand an important mechanism underlying chronic pain in humans, and provides a new treatment target.

Lymph nodes reveal more about mechanisms of autoimmunity

Two recent papers show that studying lymph nodes reveals details of the mechanisms of autoimmunity.

Multiple heart-related conditions linked to triple dementia risk, regardless of genetics

Having multiple conditions that affect the heart is linked to a greater risk of dementia than having high genetic risk, according to a large-scale new study.

NDCN research presented at Myasthenia Gravis conference

The 14th Quinquennial Myasthenia Gravis Federation of America International Conference was recently held in Miami with 450 delegates attending in person, including over 100 from industry.

Magnetic signatures of the brain characterised in UK Biobank imaging study

A study published this week in Nature Neuroscience demonstrates how studying the magnetic properties of tissue may provide a unique window into brain health and disease.